Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VistaGen Therapeutics Board of Directors APPROVED RECENT TRANSACTION
Jon S. Saxe,
Chairman
Brian J. Underdown, Ph.D.,
Director
H. Ralph Snodgrass, Ph.D.,
Founder, President and Chief Scientific Officer
Shawn K. Singh, J.D.
Chief Executive Officer
Management Team
Shawn K. Singh, J.D.
Chief Executive Officer, Director
H. Ralph Snodgrass, Ph.D.
Founder, President and Chief Scientific Officer, Director
Jerrold D. Dotson, CPA
Acting Chief Financial Officer
A. Franklin Rice, MBA
VP of Corporate Development, Secretary
Scientific Advisory Board
Gordon Keller, Ph.D.
Chairman, Director, McEwen Centre for Regenerative Medicine, University Health Network
DIRECTOR'S OF VSTA APPROVED RECENT TRANSACTION LIKE IT OR NOT
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.
Bergamo Acquisition Corp Announces Financial Compliance Update
Bergamo Acquisition Corp. (USOTC:BGMO)
August 16,2013
Bergamo Acquisition Corp. (OTC: BGMO) Board of Directors are currently in the process of updating the financial compliance's with OTC markets and various related authorities by also submitting the relevant documents attesting to the authenticity of all the previous announcements on the OTC markets.
The senior management of the company is presently visiting their subsidiaries abroad in order to make the final financial arrangements connected with its previous announcements.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results, events and performances could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause the Company'S actual results, expressed or implied, to differ materially from expected results. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making an investment decision.
Bergamo Acquisition Corp.
Hillard Herzog, 702-269-4523
IR@BergamoCorp.com
www.BergamoCorp.com
or
Investor Relations:
The Eversull Group, Inc.
Jack Eversull, President, 972-571-1624
Fax: 214-469-2361
jack@theeversullgroup.com
http://ih.advfn.com/p.php?pid=nmona&article=58848559&symbol=BGMO
Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."
VSTA Developing Promising LiverSafe3D™ Bioassay System to Predict Liver Toxicity
In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, biotech company VistaGen Therapeutics is developing a novel human liver cell-based bioassay system, LiverSafe3D™.
VistaGen believes it can use its technology to provide clinically relevant biological information about a new drug candidate early in the drug development process, before time and money are spent on clinical trials.
To do this, VistaGen focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The LiverSafe3D system is designed to predict liver toxicity and metabolism issues in connection with VistaGen’s drug rescue activities.
In a poster presentation entitled “Semi–quantitative assay of CYP3A4 allows the identification and selection of mature human stem cell derived hepatocytes,” Dr. Kristina Bonham, senior scientist, Hepatocyte Biology Project Leader, earlier this year presented data indicating that the LiverSafe 3D bioassay can monitor the induction of the key metabolic enzyme, CYP3A4, and its expression level.
This data suggests that VistaGen’s liver cells contain functional properties of mature adult liver cells, which would allow for multiple functional analyses and provides a system to evaluate the effects of drug candidates on CYP3A4 expression and liver function.
VistaGen Therapeutics announced they reduced the number of shares of common stock the Company is authorized to issue from 400,000,000 shares to 200,000,000 shares.
NO PR. RETRACTION FROM VISTAGEN FULLY REPORTING COMPANY
VISTAGEN THERAPEUTICS ON CANADAS LARGEST NEWS BROADCASTER
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube(TM), with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
VistaGen's small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.
Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.
Value of VSTA is Seen in Pharmaceutical Disasters
The importance of the work being done at VistaGen Therapeutics, developers of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates, can be seen in the clinical disasters occasionally experienced by major players in the pharmaceutical industry. A recent article (http://dtg.fm/v3V4) by Valorie Sands in Minyanville, an Internet-based financial media and publishing company, gives an idea of the risks pharmacy companies face, and the need for better and earlier testing.
The article points to the 2010 withdrawal by Pfizer of Thelin (sitaxentan), a medication for treating pulmonary arterial hypertension that had been approved for marketing in Europe, Canada, and Australia, and was undergoing final clinical trials in the U.S., when liver toxicity claimed two lives. In 2008, Pfizer had paid roughly $195 million in a cash tender offer to acquire Encysive Pharmaceuticals to get the drug, which had generated sales of over $44 million for Pfizer in the 9 months prior to its withdrawal.
Another example referred to in the article was a class of highly effective anticancer drugs called anthracycines. In spite of their effectiveness in the treatment of lung cancer, breast cancer, lymphomas, leukemias, and other types of cancers, the use of these drugs is now considerably limited due to the later discovery of significant cardiotoxicity associated with anthracycines.
Overall, toxicity issues end up affecting many new drugs, often late in testing, or even when they have made it all the way to market. The risk is not only to the physical health of patients, but also to the fiscal health of the companies that have invested hundreds of millions in a drug’s development. VistaGen proposes a solution to the problem through its unique Human Clinical Trials in a Test Tube stem cell based platform designed to provide superior heart and liver toxicity testing right in the laboratory, well before clinical trials or market exposure.
For additional information, visit http://www.VistaGen.com
VSTA Developing Promising LiverSafe3D™ Bioassay System to Predict Liver Toxicity
In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, biotech company VistaGen Therapeutics is developing a novel human liver cell-based bioassay system, LiverSafe3D™.
VistaGen believes it can use its technology to provide clinically relevant biological information about a new drug candidate early in the drug development process, before time and money are spent on clinical trials.
To do this, VistaGen focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The LiverSafe3D system is designed to predict liver toxicity and metabolism issues in connection with VistaGen’s drug rescue activities.
In a poster presentation entitled “Semi–quantitative assay of CYP3A4 allows the identification and selection of mature human stem cell derived hepatocytes,” Dr. Kristina Bonham, senior scientist, Hepatocyte Biology Project Leader, earlier this year presented data indicating that the LiverSafe 3D bioassay can monitor the induction of the key metabolic enzyme, CYP3A4, and its expression level.
This data suggests that VistaGen’s liver cells contain functional properties of mature adult liver cells, which would allow for multiple functional analyses and provides a system to evaluate the effects of drug candidates on CYP3A4 expression and liver function.
Bergamo Acquisition Corp Announces Financial Compliance Update
Bergamo Acquisition Corp. (USOTC:BGMO)
August 16,2013
Bergamo Acquisition Corp. (OTC: BGMO) Board of Directors are currently in the process of updating the financial compliance's with OTC markets and various related authorities by also submitting the relevant documents attesting to the authenticity of all the previous announcements on the OTC markets.
The senior management of the company is presently visiting their subsidiaries abroad in order to make the final financial arrangements connected with its previous announcements.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results, events and performances could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause the Company'S actual results, expressed or implied, to differ materially from expected results. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making an investment decision.
Bergamo Acquisition Corp.
Hillard Herzog, 702-269-4523
IR@BergamoCorp.com
www.BergamoCorp.com
or
Investor Relations:
The Eversull Group, Inc.
Jack Eversull, President, 972-571-1624
Fax: 214-469-2361
jack@theeversullgroup.com
http://ih.advfn.com/p.php?pid=nmona&article=58848559&symbol=BGMO
Value of VSTA is Seen in Pharmaceutical Disasters
The importance of the work being done at VistaGen Therapeutics, developers of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates, can be seen in the clinical disasters occasionally experienced by major players in the pharmaceutical industry. A recent article (http://dtg.fm/v3V4) by Valorie Sands in Minyanville, an Internet-based financial media and publishing company, gives an idea of the risks pharmacy companies face, and the need for better and earlier testing.
The article points to the 2010 withdrawal by Pfizer of Thelin (sitaxentan), a medication for treating pulmonary arterial hypertension that had been approved for marketing in Europe, Canada, and Australia, and was undergoing final clinical trials in the U.S., when liver toxicity claimed two lives. In 2008, Pfizer had paid roughly $195 million in a cash tender offer to acquire Encysive Pharmaceuticals to get the drug, which had generated sales of over $44 million for Pfizer in the 9 months prior to its withdrawal.
Another example referred to in the article was a class of highly effective anticancer drugs called anthracycines. In spite of their effectiveness in the treatment of lung cancer, breast cancer, lymphomas, leukemias, and other types of cancers, the use of these drugs is now considerably limited due to the later discovery of significant cardiotoxicity associated with anthracycines.
Overall, toxicity issues end up affecting many new drugs, often late in testing, or even when they have made it all the way to market. The risk is not only to the physical health of patients, but also to the fiscal health of the companies that have invested hundreds of millions in a drug’s development. VistaGen proposes a solution to the problem through its unique Human Clinical Trials in a Test Tube stem cell based platform designed to provide superior heart and liver toxicity testing right in the laboratory, well before clinical trials or market exposure.
For additional information, visit http://www.VistaGen.com
VSTA Uses Proprietary Stem Cell Technology to Address Two Separate Medical Needs
VistaGen Therapeutics is applying its innovative stem cell technologies in two separate but related fields. On the one hand, the company has developed one of the most important new approaches to the field of drug testing in decades, the use of stem cells to create their proprietary Human Clinical Trials in a Test Tube bioassay platform, which is designed to avoid the extensive time and expense involved in animal or other traditional tests. But VistaGen is also exploring a number of opportunities in the field of regenerative cell therapy, focused on blood, cartilage, heart, liver, and pancreas cells, each based on the proprietary stem cell differentiation and production capabilities of the company’s testing platform.
VistaGen’s stem cell based drug testing technology has resulted in CardioSafe 3D, a three-dimensional in vitro bioassay system for accurately assessing toxic (as well as non-toxic) effects of small-molecule drug candidates on human heart tissue. They are also finalizing the development of LiverSafe 3D, offering early and cost effective drug effect testing for the liver. VistaGen’s primary near-term goal for their testing technology is to use CardioSafe 3D, and eventually LiverSafe 3D, for drug rescue, to recapture substantial potential value associated with the pharmaceutical industry’s prior investment in drug discovery and development, involving once-promising small molecule drug candidates that were discontinued due to safety issues related to unexpected heart or liver toxicity or drug metabolism issues.
On the regenerative cell therapy side of things, VistaGen has developed AV-101, an orally available small molecule prodrug candidate, aimed at the needs of the multi-billion dollar neurological disease and disorders market. AV-101 has successfully completed Phase I development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects approximately 1.8 million people in the U.S. alone. The company has already been awarded over $8.3 million of grant funding by the National Institutes of Health to support preclinical and Phase I clinical development of AV-101. The company believes that AV-101 may also be a candidate for development as a therapeutic alternative for depression, epilepsy, and Parkinson’s disease.
For additional information, visit http://www.VistaGen.com
VSTA to Address U.S. Pharmaceutical “Crisis” with Innovative Stem Cell-based Technology
Since its inception in 1998, the U.S. National Institutes of Health (NIH) has awarded biotech small-cap VistaGen Therapeutics with $11.3 million in R&D grants, including $2.3 million to support the company’s development of its Human Clinical Trials in a Test Tube™ platform, and $8.8 million for nonclinical and phase 1 clinical development of AV-101, the company’s lead small molecule drug candidate.
The company has also been awarded approximately $1.0 million of grant funding from the California Institute for Regenerative Medicine (CIRM) pertaining to R&D related to liver cells.
VSTA’s corporate development strategy hinges on strategic collaborations, which provides the company valuable access to cutting-edge expertise at a lower price than it would cost to develop the expertise internally. Ideal third-party collaborators include academic research institutions for stem cell research; CROs, which offer regulatory and drug development expertise; and medicinal chemistry companies that analyze drug rescue candidates and generate drug rescue variants.
Complementary to this strategy, VSTA in 2007 entered into a long-term sponsored stem cell R&D collaboration with University Health Network (UNH), one of the world’s largest research hospitals and an affiliate of world-renowned stem cell research facility, the McEwen Centre for Regenerative Medicine, for which VSTA co-founder Dr. Gordon Keller is the director. VSTA has also established several other strategic collaborations.
Leveraging these grants, collaborations and the expertise of Dr. Keller and his team of scientists, VSTA believes it has emerged as the first stem cell company focused primarily on stem cell technology-based drug rescue. Through a combination of licenses, patents, and trade secret laws, VSTA has secured intellectual property rights to the technology underlying its Human Clinical Trials in a Test Tube™. VSTA currently owns or has licensed 43 issued U.S. patents and 12 U.S. patent applications pertaining to its stem cell technologies.
VSTA says the U.S. pharmaceutical industry is facing a “drug discovery and development crisis,” signaled by the fact that while the pharmaceutical industry invested nearly $49 billion in R&D, a total of only 39 novel drugs were approved by the FDA. The hang-up centers on high costs of drug development and non-approval due to safety issues of the candidates.
VSTA aims to buck this trend by leveraging its human cells derived from its hPSC technology, which it considers superior to major toxicological testing systems that use animal cells and cellular assays based on transformed cell lines and human cadaver cells, which at best only approximate human biology. VSTA believes it can develop better medicine by using its technology to provide clinically relevant biological information about a new drug candidate early in the drug development process, before time and money are spent on clinical trials.
For more information, visit http://www.VistaGen.com
VSTA Offers Innovative Technological Solution to Ongoing Drug Discovery and Development Crisis
California based VistaGen Therapeutics, a biotech company focused on using their proprietary pluripotent stem cell technology for superior predictive toxicology and drug metabolism screening, is aggressively pursuing an innovative drug development path with unusually high profit potential. The company intends to identify once-promising small molecule drug candidates on which large amounts of research and development money has already been spent, but which have been discontinued and “shelved” due to unexpected safety concerns relating to heart or liver toxicity. The company’s one-of-a-kind bioassay platform, called Human Clinical Trials in a Test Tube, allows highly cost effective toxicity testing for heart and liver cells right in the laboratory, offering a unique way to quickly test and modify drug candidates, maintaining drug efficacy while eliminating toxicity.
VistaGen’s strategy leverages their developing stem cell technology based bioassay systems, CardioSafe 3D™ and LiverSafe 3D™, as well as their network of strategic relationships, and substantial prior third-party investment in drug discovery and development
The company’s approach is buoyed by the ongoing drug discovery and development crisis being experienced by the U.S. pharmaceutical industry. Last year, in spite of a $49 billion R&D investment by the pharmaceutical industry, the FDA’s Center for Drug Evaluation and Research approved only 39 novel NME (New Molecular Entity) drugs. Since 2003, the FDA has approved an average of only 26 NME’s annually. The high cost of drug development, coupled with this very low approval rate, means that such drug failures are a serious economic drain on the industry, and a potential economic catastrophe for the developing company.
A big part of the problem comes from known limitations of the industry’s current toxicological testing methodology, which relies primarily on animal models, transformed cell lines, or human cadaver cells. It’s an approach that can only approximate live human biology, and can lead to unpleasant surprises after millions or billions of dollars have already been spent on drug development.
VistaGen’s system offers mature human cells for more accurate and timely testing. It’s a technology of huge potential value to the industry, but also of value to VistaGen as a base for developing their own line of drug rescue variants.
For additional information, visit http://www.VistaGen.com
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
Seasoned Biotech Executive to Lead VistaGen’s Stem Cell-based Clinical Trials in a Test TubeTM Platform Focused on Transforming the Way New Drugs Are Discovered and Developed
SOUTH SAN FRANCISCO, CA (August 20, 2009) — VistaGen Therapeutics has named Shawn K. Singh as Chief Executive Officer. Mr. Singh was Managing Principal of Cato BioVentures, one of VistaGen’s largest institutional investors, and the Company’s President (part-time). Mr. Singh also served as Chief Business Officer, President, CEO or Chairman of five different biopharmaceutical companies, as well as CBO and General Counsel of Cato Research Ltd., a global contract research and development organization. Ralph Snodgrass, PhD, VistaGen’s founder and former CEO, will continue to serve as President and Chief Scientific Officer. Both Dr. Snodgrass and Mr. Singh are members of VistaGen’s Board of Directors.
VistaGen is one of the leading companies worldwide focused on using the power of stem cell technologies to transform the way new medicines are discovered and developed. The Company’s internal programs are focused on discovery and development of next generation drugs to treat Alzheimer’s, cancer and diabetes.
“VistaGen is a dynamic company marked by visionary technology, a rich history of innovation and a remarkable ability to navigate through intense economic and political headwinds without veering off course,” said Shawn Singh. “We believe better human response information can lead to better medicine. By using our Clinical Trials in a Test TubeTM platform to focus on how new drugs work in the body and how they interact with people with specific genetic differences, we are confident that our founding vision can become a medical reality.” He added, “I am honored to have the opportunity to lead a team so passionately focused on commercializing science that will make a difference.”
“I have worked with Shawn for eight years, and I strongly support both his appointment as CEO and my new role as President and Chief Scientific Officer,” said Dr. Ralph Snodgrass. “Together, these changes significantly broaden and strengthen our management team, enabling us to accomplish more than ever before, both commercially and scientifically, and I look forward to this new phase in our corporate development.”
“VistaGen is moving rapidly on many business fronts,” said Jon Saxe, VistaGen’s Chairman. “We are fortunate to have available someone of Shawn’s leadership skills and extensive experience with a wide range of life science companies and technologies to lead VistaGen’s efforts to realize the full commercial potential of its stem cell technologies. At the same time, the continued service of our founder, Ralph Snodgrass, as President and CSO is invaluable. Shawn’s availability as CEO on a full- time basis will enable Ralph to devote more time to strategic vision and scientific development of the platform, including collaborations with commercial partners and our esteemed network of academic stem cell research centers.”
VistaGen’s stem cell-based Clinical Trials in a Test TubeTM platform is focused on creating in human cells a comprehensive picture of the intricate details of human biology and human disease in ways that conventional animal models and non-human cell culture systems can only approximate. This enables drug developers to test for drug toxicity and efficacy in the lab quickly and efficiently, before costly human clinical trials.
Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster. He later served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), Chief Business Officer and General Counsel of Cato Research Ltd., a global contract research and development organization, Chief Operating Officer and Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research Ltd, President of Echo Therapeutics (OTCBB: ECTE), Chairman of the Board and President of Durham Pharmaceuticals, President of Artemis Neuroscience, and Chief Executive Officer of Hemodynamic Therapeutics.
Mr. Singh received a B.A. from the University of California, Berkeley, and a J.D. from The University of Maryland School of Law. He currently serves on the Board of Directors of Echo Therapeutics and Hemodynamic Therapeutics and as a strategic advisor to Cato BioVentures and several other private biopharmaceutical companies.
VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen’s Clinical Trials in a Test TubeTM platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry’s ability to deliver innovative drugs for some of the world’s most challenging diseases and conditions. For more information, visit: http://www.VistaGen.com
The strategy of VistaGen Therapeutics, a California based stem-cell technology company, is primed to drive rapid growth because of its unique structure. VistaGen is a developer of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates. It provides a distinctive way of determining potential drug toxicity well before the time and expense involved in performing animal or human trials.
The history of the pharmaceutical industry is one littered with drug candidates that were developed, and sometimes even released to the public, only to discover later that there were heart or liver toxicity issues. These drugs were then often shelved, resulting in a massive loss of invested time and money for the pharmaceutical company involved. For drug companies around the world it’s a major problem. However, for VistaGen it represents a major opportunity.
VistaGen’s plan is to use their proprietary Human Clinical Trials in a Test Tube stem cell based platform, a novel bioassay system that provides toxicity testing right in the laboratory, to build a portfolio of drug rescue variants from once-promising but discontinued drug candidates. Considering the fact that development costs for a new drug can easily exceed $1 billion, VistaGen sees these shelved drugs as a veritable diamond mine which it now has the means to tap. It’s like having someone run a 20-mile marathon for you, and then letting you step in near the end to cross the finish line.
Specifically, VistaGen believes each lead drug rescue variant will have the potential to be a viable new drug candidate in which VistaGen can have significant economic participation rights, such as up-front and development milestone payments and royalties on commercial sales. Its valuable technology also sets the company up as a potential takeover target.
For additional information, visit http://www.VistaGen.com
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.
Unregistered Sales of Equity Securities.
On June 27, 2013, pursuant to the Securities Purchase Agreement and the schedule set forth in the Amendment, the Company issued to Autilion an aggregate total of 50,000 shares of the Company’s common stock (the “ Shares ”) for $0.50 per share, resulting in proceeds to the Company of $25,000.
The Shares were offered and sold in a transaction exempt from registration under the Securities Act of 1933, as amended (“ Securities Act ”), in reliance on Section 4(2) thereof and Rule 506 of Regulation D thereunder. Autilion represented that it was an “accredited investor” as defined in Regulation D. The proceeds from the sale of the Shares will be used for general corporate purposes
"Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," stated Shawn K. Singh, VistaGen's Chief Executive Officer. "Upon the closing of this transformative financing, our strong long-term financial position will enhance substantially our ability to drive our core programs to valuable commercial outcomes."
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp., a global diversified investment holding company.
For 72 million shares of restricted common stock
VistaGen signed a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp., a global diversified investment holding company.
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, VSTA is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. VSTA also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform
CPA L.L. BRADFORD WOULD NOT SIGN OFF ON FRAUDULENT HSBC BANK STATEMENT
http://bergamocorp.com/cpa-letter-1-13/#/2
VistaGen Therapeutics Board of Directors APPROVED RECENT TRANSACTION
Jon S. Saxe,
Chairman
Brian J. Underdown, Ph.D.,
Director
H. Ralph Snodgrass, Ph.D.,
Founder, President and Chief Scientific Officer
Shawn K. Singh, J.D.
Chief Executive Officer
Management Team
Shawn K. Singh, J.D.
Chief Executive Officer, Director
H. Ralph Snodgrass, Ph.D.
Founder, President and Chief Scientific Officer, Director
Jerrold D. Dotson, CPA
Acting Chief Financial Officer
A. Franklin Rice, MBA
VP of Corporate Development, Secretary
Scientific Advisory Board
Gordon Keller, Ph.D.
Chairman, Director, McEwen Centre for Regenerative Medicine, University Health Network
DIRECTOR'S OF VSTA APPROVED RECENT TRANSACTION LIKE IT OR NOT
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.
Bergamo Acquisition Corp Announces Financial Compliance Update
Bergamo Acquisition Corp. (USOTC:BGMO)
August 16,2013
Bergamo Acquisition Corp. (OTC: BGMO) Board of Directors are currently in the process of updating the financial compliance's with OTC markets and various related authorities by also submitting the relevant documents attesting to the authenticity of all the previous announcements on the OTC markets.
The senior management of the company is presently visiting their subsidiaries abroad in order to make the final financial arrangements connected with its previous announcements.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results, events and performances could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause the Company'S actual results, expressed or implied, to differ materially from expected results. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making an investment decision.
Bergamo Acquisition Corp.
Hillard Herzog, 702-269-4523
IR@BergamoCorp.com
www.BergamoCorp.com
or
Investor Relations:
The Eversull Group, Inc.
Jack Eversull, President, 972-571-1624
Fax: 214-469-2361
jack@theeversullgroup.com
http://ih.advfn.com/p.php?pid=nmona&article=58848559&symbol=BGMO
Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."
VSTA Developing Promising LiverSafe3D™ Bioassay System to Predict Liver Toxicity
In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, biotech company VistaGen Therapeutics is developing a novel human liver cell-based bioassay system, LiverSafe3D™.
VistaGen believes it can use its technology to provide clinically relevant biological information about a new drug candidate early in the drug development process, before time and money are spent on clinical trials.
To do this, VistaGen focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The LiverSafe3D system is designed to predict liver toxicity and metabolism issues in connection with VistaGen’s drug rescue activities.
In a poster presentation entitled “Semi–quantitative assay of CYP3A4 allows the identification and selection of mature human stem cell derived hepatocytes,” Dr. Kristina Bonham, senior scientist, Hepatocyte Biology Project Leader, earlier this year presented data indicating that the LiverSafe 3D bioassay can monitor the induction of the key metabolic enzyme, CYP3A4, and its expression level.
This data suggests that VistaGen’s liver cells contain functional properties of mature adult liver cells, which would allow for multiple functional analyses and provides a system to evaluate the effects of drug candidates on CYP3A4 expression and liver function.
VistaGen Therapeutics announced they reduced the number of shares of common stock the Company is authorized to issue from 400,000,000 shares to 200,000,000 shares.
NO PR. RETRACTION FROM VISTAGEN FULLY REPORTING COMPANY
VISTAGEN THERAPEUTICS ON CANADAS LARGEST NEWS BROADCASTER
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube(TM), with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
VistaGen's small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.
Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.
Value of VSTA is Seen in Pharmaceutical Disasters
The importance of the work being done at VistaGen Therapeutics, developers of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates, can be seen in the clinical disasters occasionally experienced by major players in the pharmaceutical industry. A recent article (http://dtg.fm/v3V4) by Valorie Sands in Minyanville, an Internet-based financial media and publishing company, gives an idea of the risks pharmacy companies face, and the need for better and earlier testing.
The article points to the 2010 withdrawal by Pfizer of Thelin (sitaxentan), a medication for treating pulmonary arterial hypertension that had been approved for marketing in Europe, Canada, and Australia, and was undergoing final clinical trials in the U.S., when liver toxicity claimed two lives. In 2008, Pfizer had paid roughly $195 million in a cash tender offer to acquire Encysive Pharmaceuticals to get the drug, which had generated sales of over $44 million for Pfizer in the 9 months prior to its withdrawal.
Another example referred to in the article was a class of highly effective anticancer drugs called anthracycines. In spite of their effectiveness in the treatment of lung cancer, breast cancer, lymphomas, leukemias, and other types of cancers, the use of these drugs is now considerably limited due to the later discovery of significant cardiotoxicity associated with anthracycines.
Overall, toxicity issues end up affecting many new drugs, often late in testing, or even when they have made it all the way to market. The risk is not only to the physical health of patients, but also to the fiscal health of the companies that have invested hundreds of millions in a drug’s development. VistaGen proposes a solution to the problem through its unique Human Clinical Trials in a Test Tube stem cell based platform designed to provide superior heart and liver toxicity testing right in the laboratory, well before clinical trials or market exposure.
For additional information, visit http://www.VistaGen.com
Bergamo Acquisition Corp Announces Financial Compliance Update
Bergamo Acquisition Corp. (USOTC:BGMO)
August 16,2013
Bergamo Acquisition Corp. (OTC: BGMO) Board of Directors are currently in the process of updating the financial compliance's with OTC markets and various related authorities by also submitting the relevant documents attesting to the authenticity of all the previous announcements on the OTC markets.
The senior management of the company is presently visiting their subsidiaries abroad in order to make the final financial arrangements connected with its previous announcements.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results, events and performances could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause the Company'S actual results, expressed or implied, to differ materially from expected results. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making an investment decision.
Bergamo Acquisition Corp.
Hillard Herzog, 702-269-4523
IR@BergamoCorp.com
www.BergamoCorp.com
or
Investor Relations:
The Eversull Group, Inc.
Jack Eversull, President, 972-571-1624
Fax: 214-469-2361
jack@theeversullgroup.com
http://ih.advfn.com/p.php?pid=nmona&article=58848559&symbol=BGMO
Value of VSTA is Seen in Pharmaceutical Disasters
The importance of the work being done at VistaGen Therapeutics, developers of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates, can be seen in the clinical disasters occasionally experienced by major players in the pharmaceutical industry. A recent article (http://dtg.fm/v3V4) by Valorie Sands in Minyanville, an Internet-based financial media and publishing company, gives an idea of the risks pharmacy companies face, and the need for better and earlier testing.
The article points to the 2010 withdrawal by Pfizer of Thelin (sitaxentan), a medication for treating pulmonary arterial hypertension that had been approved for marketing in Europe, Canada, and Australia, and was undergoing final clinical trials in the U.S., when liver toxicity claimed two lives. In 2008, Pfizer had paid roughly $195 million in a cash tender offer to acquire Encysive Pharmaceuticals to get the drug, which had generated sales of over $44 million for Pfizer in the 9 months prior to its withdrawal.
Another example referred to in the article was a class of highly effective anticancer drugs called anthracycines. In spite of their effectiveness in the treatment of lung cancer, breast cancer, lymphomas, leukemias, and other types of cancers, the use of these drugs is now considerably limited due to the later discovery of significant cardiotoxicity associated with anthracycines.
Overall, toxicity issues end up affecting many new drugs, often late in testing, or even when they have made it all the way to market. The risk is not only to the physical health of patients, but also to the fiscal health of the companies that have invested hundreds of millions in a drug’s development. VistaGen proposes a solution to the problem through its unique Human Clinical Trials in a Test Tube stem cell based platform designed to provide superior heart and liver toxicity testing right in the laboratory, well before clinical trials or market exposure.
For additional information, visit http://www.VistaGen.com
VSTA Uses Proprietary Stem Cell Technology to Address Two Separate Medical Needs
VistaGen Therapeutics is applying its innovative stem cell technologies in two separate but related fields. On the one hand, the company has developed one of the most important new approaches to the field of drug testing in decades, the use of stem cells to create their proprietary Human Clinical Trials in a Test Tube bioassay platform, which is designed to avoid the extensive time and expense involved in animal or other traditional tests. But VistaGen is also exploring a number of opportunities in the field of regenerative cell therapy, focused on blood, cartilage, heart, liver, and pancreas cells, each based on the proprietary stem cell differentiation and production capabilities of the company’s testing platform.
VistaGen’s stem cell based drug testing technology has resulted in CardioSafe 3D, a three-dimensional in vitro bioassay system for accurately assessing toxic (as well as non-toxic) effects of small-molecule drug candidates on human heart tissue. They are also finalizing the development of LiverSafe 3D, offering early and cost effective drug effect testing for the liver. VistaGen’s primary near-term goal for their testing technology is to use CardioSafe 3D, and eventually LiverSafe 3D, for drug rescue, to recapture substantial potential value associated with the pharmaceutical industry’s prior investment in drug discovery and development, involving once-promising small molecule drug candidates that were discontinued due to safety issues related to unexpected heart or liver toxicity or drug metabolism issues.
On the regenerative cell therapy side of things, VistaGen has developed AV-101, an orally available small molecule prodrug candidate, aimed at the needs of the multi-billion dollar neurological disease and disorders market. AV-101 has successfully completed Phase I development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects approximately 1.8 million people in the U.S. alone. The company has already been awarded over $8.3 million of grant funding by the National Institutes of Health to support preclinical and Phase I clinical development of AV-101. The company believes that AV-101 may also be a candidate for development as a therapeutic alternative for depression, epilepsy, and Parkinson’s disease.
For additional information, visit http://www.VistaGen.com
VSTA to Address U.S. Pharmaceutical “Crisis” with Innovative Stem Cell-based Technology
Since its inception in 1998, the U.S. National Institutes of Health (NIH) has awarded biotech small-cap VistaGen Therapeutics with $11.3 million in R&D grants, including $2.3 million to support the company’s development of its Human Clinical Trials in a Test Tube™ platform, and $8.8 million for nonclinical and phase 1 clinical development of AV-101, the company’s lead small molecule drug candidate.
The company has also been awarded approximately $1.0 million of grant funding from the California Institute for Regenerative Medicine (CIRM) pertaining to R&D related to liver cells.
VSTA’s corporate development strategy hinges on strategic collaborations, which provides the company valuable access to cutting-edge expertise at a lower price than it would cost to develop the expertise internally. Ideal third-party collaborators include academic research institutions for stem cell research; CROs, which offer regulatory and drug development expertise; and medicinal chemistry companies that analyze drug rescue candidates and generate drug rescue variants.
Complementary to this strategy, VSTA in 2007 entered into a long-term sponsored stem cell R&D collaboration with University Health Network (UNH), one of the world’s largest research hospitals and an affiliate of world-renowned stem cell research facility, the McEwen Centre for Regenerative Medicine, for which VSTA co-founder Dr. Gordon Keller is the director. VSTA has also established several other strategic collaborations.
Leveraging these grants, collaborations and the expertise of Dr. Keller and his team of scientists, VSTA believes it has emerged as the first stem cell company focused primarily on stem cell technology-based drug rescue. Through a combination of licenses, patents, and trade secret laws, VSTA has secured intellectual property rights to the technology underlying its Human Clinical Trials in a Test Tube™. VSTA currently owns or has licensed 43 issued U.S. patents and 12 U.S. patent applications pertaining to its stem cell technologies.
VSTA says the U.S. pharmaceutical industry is facing a “drug discovery and development crisis,” signaled by the fact that while the pharmaceutical industry invested nearly $49 billion in R&D, a total of only 39 novel drugs were approved by the FDA. The hang-up centers on high costs of drug development and non-approval due to safety issues of the candidates.
VSTA aims to buck this trend by leveraging its human cells derived from its hPSC technology, which it considers superior to major toxicological testing systems that use animal cells and cellular assays based on transformed cell lines and human cadaver cells, which at best only approximate human biology. VSTA believes it can develop better medicine by using its technology to provide clinically relevant biological information about a new drug candidate early in the drug development process, before time and money are spent on clinical trials.
For more information, visit http://www.VistaGen.com
VSTA Offers Innovative Technological Solution to Ongoing Drug Discovery and Development Crisis
California based VistaGen Therapeutics, a biotech company focused on using their proprietary pluripotent stem cell technology for superior predictive toxicology and drug metabolism screening, is aggressively pursuing an innovative drug development path with unusually high profit potential. The company intends to identify once-promising small molecule drug candidates on which large amounts of research and development money has already been spent, but which have been discontinued and “shelved” due to unexpected safety concerns relating to heart or liver toxicity. The company’s one-of-a-kind bioassay platform, called Human Clinical Trials in a Test Tube, allows highly cost effective toxicity testing for heart and liver cells right in the laboratory, offering a unique way to quickly test and modify drug candidates, maintaining drug efficacy while eliminating toxicity.
VistaGen’s strategy leverages their developing stem cell technology based bioassay systems, CardioSafe 3D™ and LiverSafe 3D™, as well as their network of strategic relationships, and substantial prior third-party investment in drug discovery and development
The company’s approach is buoyed by the ongoing drug discovery and development crisis being experienced by the U.S. pharmaceutical industry. Last year, in spite of a $49 billion R&D investment by the pharmaceutical industry, the FDA’s Center for Drug Evaluation and Research approved only 39 novel NME (New Molecular Entity) drugs. Since 2003, the FDA has approved an average of only 26 NME’s annually. The high cost of drug development, coupled with this very low approval rate, means that such drug failures are a serious economic drain on the industry, and a potential economic catastrophe for the developing company.
A big part of the problem comes from known limitations of the industry’s current toxicological testing methodology, which relies primarily on animal models, transformed cell lines, or human cadaver cells. It’s an approach that can only approximate live human biology, and can lead to unpleasant surprises after millions or billions of dollars have already been spent on drug development.
VistaGen’s system offers mature human cells for more accurate and timely testing. It’s a technology of huge potential value to the industry, but also of value to VistaGen as a base for developing their own line of drug rescue variants.
For additional information, visit http://www.VistaGen.com
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
Seasoned Biotech Executive to Lead VistaGen’s Stem Cell-based Clinical Trials in a Test TubeTM Platform Focused on Transforming the Way New Drugs Are Discovered and Developed
SOUTH SAN FRANCISCO, CA (August 20, 2009) — VistaGen Therapeutics has named Shawn K. Singh as Chief Executive Officer. Mr. Singh was Managing Principal of Cato BioVentures, one of VistaGen’s largest institutional investors, and the Company’s President (part-time). Mr. Singh also served as Chief Business Officer, President, CEO or Chairman of five different biopharmaceutical companies, as well as CBO and General Counsel of Cato Research Ltd., a global contract research and development organization. Ralph Snodgrass, PhD, VistaGen’s founder and former CEO, will continue to serve as President and Chief Scientific Officer. Both Dr. Snodgrass and Mr. Singh are members of VistaGen’s Board of Directors.
VistaGen is one of the leading companies worldwide focused on using the power of stem cell technologies to transform the way new medicines are discovered and developed. The Company’s internal programs are focused on discovery and development of next generation drugs to treat Alzheimer’s, cancer and diabetes.
“VistaGen is a dynamic company marked by visionary technology, a rich history of innovation and a remarkable ability to navigate through intense economic and political headwinds without veering off course,” said Shawn Singh. “We believe better human response information can lead to better medicine. By using our Clinical Trials in a Test TubeTM platform to focus on how new drugs work in the body and how they interact with people with specific genetic differences, we are confident that our founding vision can become a medical reality.” He added, “I am honored to have the opportunity to lead a team so passionately focused on commercializing science that will make a difference.”
“I have worked with Shawn for eight years, and I strongly support both his appointment as CEO and my new role as President and Chief Scientific Officer,” said Dr. Ralph Snodgrass. “Together, these changes significantly broaden and strengthen our management team, enabling us to accomplish more than ever before, both commercially and scientifically, and I look forward to this new phase in our corporate development.”
“VistaGen is moving rapidly on many business fronts,” said Jon Saxe, VistaGen’s Chairman. “We are fortunate to have available someone of Shawn’s leadership skills and extensive experience with a wide range of life science companies and technologies to lead VistaGen’s efforts to realize the full commercial potential of its stem cell technologies. At the same time, the continued service of our founder, Ralph Snodgrass, as President and CSO is invaluable. Shawn’s availability as CEO on a full- time basis will enable Ralph to devote more time to strategic vision and scientific development of the platform, including collaborations with commercial partners and our esteemed network of academic stem cell research centers.”
VistaGen’s stem cell-based Clinical Trials in a Test TubeTM platform is focused on creating in human cells a comprehensive picture of the intricate details of human biology and human disease in ways that conventional animal models and non-human cell culture systems can only approximate. This enables drug developers to test for drug toxicity and efficacy in the lab quickly and efficiently, before costly human clinical trials.
Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster. He later served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), Chief Business Officer and General Counsel of Cato Research Ltd., a global contract research and development organization, Chief Operating Officer and Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research Ltd, President of Echo Therapeutics (OTCBB: ECTE), Chairman of the Board and President of Durham Pharmaceuticals, President of Artemis Neuroscience, and Chief Executive Officer of Hemodynamic Therapeutics.
Mr. Singh received a B.A. from the University of California, Berkeley, and a J.D. from The University of Maryland School of Law. He currently serves on the Board of Directors of Echo Therapeutics and Hemodynamic Therapeutics and as a strategic advisor to Cato BioVentures and several other private biopharmaceutical companies.
VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen’s Clinical Trials in a Test TubeTM platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry’s ability to deliver innovative drugs for some of the world’s most challenging diseases and conditions. For more information, visit: http://www.VistaGen.com
The strategy of VistaGen Therapeutics, a California based stem-cell technology company, is primed to drive rapid growth because of its unique structure. VistaGen is a developer of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates. It provides a distinctive way of determining potential drug toxicity well before the time and expense involved in performing animal or human trials.
The history of the pharmaceutical industry is one littered with drug candidates that were developed, and sometimes even released to the public, only to discover later that there were heart or liver toxicity issues. These drugs were then often shelved, resulting in a massive loss of invested time and money for the pharmaceutical company involved. For drug companies around the world it’s a major problem. However, for VistaGen it represents a major opportunity.
VistaGen’s plan is to use their proprietary Human Clinical Trials in a Test Tube stem cell based platform, a novel bioassay system that provides toxicity testing right in the laboratory, to build a portfolio of drug rescue variants from once-promising but discontinued drug candidates. Considering the fact that development costs for a new drug can easily exceed $1 billion, VistaGen sees these shelved drugs as a veritable diamond mine which it now has the means to tap. It’s like having someone run a 20-mile marathon for you, and then letting you step in near the end to cross the finish line.
Specifically, VistaGen believes each lead drug rescue variant will have the potential to be a viable new drug candidate in which VistaGen can have significant economic participation rights, such as up-front and development milestone payments and royalties on commercial sales. Its valuable technology also sets the company up as a potential takeover target.
For additional information, visit http://www.VistaGen.com